Antibody biotech Diagonal Therapeutics lands $128M to pursue rare diseases

Diagonal Therapeutics has launched with $128 million to go after an orphan disease that leads to chronic anemia, and another antibody for the same rare disease that is also targeted by Merck’s newly approved drug, Winrevair. Just last week, the biotech was congratulating its chief scientific officer…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks